On April 13th, 2023, the UCB’s Global Corporate Website released a press statement
regarding the – one of two drugs being reviewed for the treatment of myasthenia gravis. The trial was led by James Howard, MD, who is a neurology professor at the 黑料网.
Read more on the School of Medicine’s Newsroom:
Also view The Lancet Neurology article: